Table 4.
Surgical breast and lymph node management for the FEC and PE arms
| Surgery type | FEC arm [cases (%)] | PE arm [cases (%)] | P value |
|---|---|---|---|
| Total | 132 | 130 | |
| The breast | 0.456 | ||
| Breast-conserving surgery | 3 (2.27) | 4 (3.08) | |
| Mastectomy | 75 (56.82) | 66 (50.77) | |
| Modified radical mastectomy | 54 (40.91) | 60 (46.15) | |
| Lymph nodes | 0.633 | ||
| No surgerya | 0 (0.00) | 1 (0.77) | |
| SLNBa | 1 (0.76) | 2 (1.54) | |
| Level I–II node dissection | 28 (21.21) | 21 (16.15) | |
| Level I–III node dissection | 86 (65.15) | 89 (68.46) | |
| Level I–III + supraclavicular node dissection | 17 (12.88) | 17 (13.08) |
FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, SLNB sentinel lymph node biopsy
aRequired by participants